A molecular sieve mixed matrix membrane, its preparation method, and its application

By preparing a molecular sieve mixed matrix membrane, the problems of poor selectivity and low clearance efficiency of hemodialysis membranes for β2-microglobulin were solved, achieving efficient and safe clearance of β2-microglobulin, improving the selectivity and clearance efficiency of the membrane, and avoiding prolonged treatment time and additional costs.

CN121372064BActive Publication Date: 2026-11-17AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202511960861.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-12-24
Publication Date
2026-11-17
Estimated Expiration
2045-12-24

AI Technical Summary

Technical Problem

Existing hemodialysis membranes have poor selectivity for β2-microglobulin and low clearance efficiency, leading to toxin accumulation. Furthermore, existing improved technologies either result in albumin loss or deterioration of biocompatibility, or increase treatment costs or time.

Method used

A molecular sieve mixed matrix membrane preparation method is adopted, in which biocompatible polymers, molecular sieves, pore-forming agents and non-aqueous organic solvents are mixed in the casting solution to form a molecular sieve mixed matrix membrane with regular pore size distribution. The combination of precise sieving and surface adsorption synergistic effect improves the hydrophilicity and blood compatibility of the membrane.

Benefits of technology

It achieves highly efficient screening and removal of β2-microglobulin, improves membrane selectivity and removal efficiency, avoids prolonged treatment time and additional costs, and has significant technical advantages.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121372064B_ABST
    Figure CN121372064B_ABST
Patent Text Reader

Abstract

This invention discloses a molecular sieve mixed matrix membrane, its preparation method, and its application, relating to the field of dialysis membrane technology. The method includes pouring a casting solution into a membrane scraper to obtain a nascent membrane; immersing the nascent membrane in an aqueous non-solvent for phase inversion to obtain a molecular sieve mixed matrix membrane; wherein the casting solution is obtained by uniformly mixing a polar polymer, molecular sieve, pore-forming agent, and a non-aqueous organic solvent, cooling to room temperature, and allowing it to stand for degassing. This invention solves the problems of poor selectivity and low clearance efficiency of β2-microglobulin in traditional hemodialysis membranes, and eliminates the need for prolonged treatment time and additional costs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a molecular sieve mixed matrix membrane, its preparation method, and its application, belonging to the field of dialysis membrane technology. Background Technology

[0002] Hemodialysis is one of the key treatments for end-stage renal disease patients to maintain life. However, the clearance rate of medium-molecular-weight toxins (such as β2-microglobulin and interleukin-6) by commonly used high-flux hemodialysis membranes, such as pure polyethersulfone (PES) and pure polysulfone (PSF), has long been low (usually around 30%). This is because the solute clearance of traditional membranes mainly relies on passive diffusion and convection, and their mass transfer efficiency decreases sharply with the increase of toxin molecular weight. At the same time, the wide pore size distribution of pure polymer membranes makes it difficult to achieve efficient sieving and selective adsorption of β2-microglobulin, resulting in the accumulation of large amounts of β2-microglobulin in the patient's body. The long-term accumulation of these toxins is closely related to dialysis-related amyloidosis, malnutrition, and cardiovascular complications, seriously restricting the long-term survival rate of patients.

[0003] Currently, several improvements have been attempted to address β2-microglobulin clearance, but all have significant limitations: High-flux retention membrane technology, while increasing membrane pore size to enhance medium-molecule permeability, carries an increased risk of albumin loss (5-10%), and the loose membrane structure leads to decreased mechanical strength, shortening its lifespan to 60-70% of traditional membranes; Combined hemodialysis and filtration therapy enhances medium-molecule clearance by increasing convection volume, but treatment time needs to be extended to 5-6 hours (traditional dialysis is 3-4 hours), requiring additional replacement fluid (approximately 15-25 L), increasing treatment costs by 30-50%; Research data shows that even with these improved technologies, the clearance rate of β2-microglobulin is still difficult to significantly improve, and long-term accumulation can still lead to serious complications such as renal osteodystrophy and carpal tunnel syndrome.

[0004] In summary, existing technologies for improving β2-microglobulin clearance either suffer from poor selectivity leading to albumin loss or deteriorated biocompatibility, or increase treatment costs due to prolonged dialysis time. These factors significantly limit the development and application of highly efficient and safe hemodialysis membranes. Summary of the Invention

[0005] The purpose of this invention is to overcome the shortcomings of the prior art and provide a molecular sieve mixed matrix membrane, its preparation method and application, which solves the problems of poor selectivity and low clearance efficiency of traditional hemodialysis membranes for β2-microglobulin, and does not require extending the treatment time or increasing additional costs.

[0006] To achieve the above objectives, the present invention is implemented using the following technical solution: In a first aspect, the present invention provides a method for preparing a molecular sieve mixed matrix membrane, comprising: The casting solution is poured into a film scraper to obtain the primary film; The nascent membrane was immersed in an aqueous non-solvent for phase transformation to obtain a molecular sieve mixed matrix membrane; The casting solution is obtained by mixing a biocompatible polymer, a molecular sieve, a pore-forming agent, and a non-aqueous organic solvent evenly, cooling it to room temperature, and allowing it to stand to degas.

[0007] Furthermore, the casting solution comprises 10-25 wt% biocompatible polymer, 1-15 wt% molecular sieve, 1-5 wt% pore-forming agent and 55-88 wt% non-aqueous organic solvent.

[0008] Furthermore, the biocompatible polymer is one or more of polyethersulfone, polysulfone, polyacrylonitrile, and polyamide.

[0009] And / or, the molecular weight range of the biocompatible polymer is 20,000 to 80,000 g / mol.

[0010] Furthermore, the molecular sieve is one or more of MCM-41 and MCM-48; And / or, the pore size range of the molecular sieve is 2~10 nm.

[0011] Furthermore, the pore-forming agent is one or more of polyvinylpyrrolidone and polyethylene glycol.

[0012] Furthermore, the non-aqueous organic solvent is one or more of N,N-dimethylacetamide, N,N-dimethylformamide, N,N-dimethylpyrrolidone, and dimethyl sulfoxide.

[0013] Furthermore, the parameters of the film scraping machine include a gap between the scraper and the clean glass substrate ranging from 150 to 250 micrometers, and scraping at a constant speed of 1 to 3 meters per minute; And / or, the settling and degassing time ranges from 12 to 24 hours.

[0014] Furthermore, the phase transformation is carried out at a temperature of 20-25°C for 20-28 hours.

[0015] In a second aspect, the present invention also provides a molecular sieve mixed matrix membrane, which is prepared by the method for preparing a molecular sieve mixed matrix membrane as described in any one of the first aspects.

[0016] Thirdly, the present invention also provides an application of a molecular sieve mixed matrix membrane, including passing blood through the molecular sieve mixed matrix membrane to remove β2-microglobulin from the blood.

[0017] Compared with the prior art, the beneficial effects achieved by the present invention are as follows: The molecular sieve used in this invention has a regular pore size distribution that is highly matched with the size of medium-molecular-weight toxins. It can specifically capture toxin molecules through precise sieving and surface adsorption synergistic effects. Furthermore, using molecular sieves as an additive can effectively improve the overall hydrophilicity and blood compatibility of the membrane. At the same time, the addition of pore-forming agents can effectively improve the dispersibility of molecular sieves in polyethersulfone matrix, avoiding membrane structure defects caused by filler agglomeration. This solves the problems of poor selectivity and low clearance efficiency of traditional hemodialysis membranes for β2-microglobulin, without extending treatment time or increasing additional costs. It has significant technical advantages and application prospects. Attached Figure Description

[0018] Figure 1 This is a schematic diagram comparing the X-ray diffraction patterns of the molecular sieve mixed matrix membranes prepared in Examples 13-17 of the present invention and the pure polymer membrane prepared in Comparative Example 1. Figure 2 This is a schematic diagram comparing the water contact angles of the molecular sieve mixed matrix membranes prepared in Examples 13-17 of the present invention and the pure polymer membrane prepared in Comparative Example 1. Figure 3 This is a schematic diagram comparing the porosity of the molecular sieve mixed matrix membranes prepared in Examples 13-17 of the present invention and the pure polymer membranes prepared in Comparative Example 1. Figure 4 This is a SEM schematic diagram of the cross-section of the molecular sieve mixed matrix membrane prepared in Example 1 of the present invention. Detailed Implementation

[0019] The present invention will be further described below with reference to the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and should not be used to limit the scope of protection of the present invention.

[0020] Example 1:

[0021] This invention provides a method for preparing a molecular sieve mixed matrix membrane, comprising the following steps: First, by mass fraction, 15 wt% polyethersulfone (PES), 3 wt% polyvinylpyrrolidone (PVP, K30) and 1 wt% molecular sieve MCM-41 (molecular sieve pore size of 3.6 nm) were dispersed in 81 wt% N,N-dimethylacetamide (DMAC) solvent and mechanically stirred at 60°C for 6 hours until a uniform and clear casting solution was formed.

[0022] Then, the casting solution is allowed to cool naturally to room temperature (about 25°C) and allowed to stand for 12 hours to deaerate, so as to completely remove the air bubbles introduced during the stirring process and obtain the deaerated casting solution.

[0023] Next, the degassed casting liquid is placed into the feed trough of the film scraper. The gap between the scraper and the clean glass substrate is controlled to be 200 micrometers. The film is scraped at a constant speed of 2 meters per minute to obtain the nascent film.

[0024] Finally, the nascent membrane was placed on a glass plate, and the entire glass plate carrying the nascent membrane was immersed in deionized water at 25°C for phase inversion for 24 hours to obtain a molecular sieve mixed matrix membrane, the cross-sectional structure of which is shown below. Figure 4 As shown, the asymmetric layered pore structure of the membrane can be clearly seen: the upper layer consists of regularly arranged vertical through-channels that are straight and interconnected, allowing water and toxins to pass through the membrane more smoothly and reducing obstacles during transport; the lower layer consists of inclined, interwoven mesh-like channels with looser pores, which on the one hand makes it less likely for the flux to decrease, and on the other hand, this flexible support structure makes the membrane more robust, avoiding the problem of easy damage to the upper layer through-channels.

[0025] Example 2:

[0026] The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 2wt%, correspondingly reducing the N,N-dimethylacetamide solvent.

[0027] Example 3:

[0028] The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 3wt%, correspondingly reducing the N,N-dimethylacetamide solvent.

[0029] Example 4:

[0030] The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 4wt%, correspondingly reducing the N,N-dimethylacetamide solvent.

[0031] Example 5:

[0032] The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 5wt%, correspondingly reducing the N,N-dimethylacetamide solvent.

[0033] Example 6:

[0034] The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 6wt%, correspondingly reducing the N,N-dimethylacetamide solvent.

[0035] Example 7:

[0036] The only difference between this embodiment and Embodiment 1 is that the pore size of the molecular sieve MCM-41 is adjusted to 4.7 nm.

[0037] Example 8:

[0038] The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 2wt%, correspondingly reducing the N,N-dimethylacetamide solvent, and the pore size of the molecular sieve MCM-41 is adjusted to 4.7nm.

[0039] Example 9:

[0040] The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 3wt%, correspondingly reducing the N,N-dimethylacetamide solvent, and the pore size of the molecular sieve MCM-41 is adjusted to 4.7nm.

[0041] Example 10: The only difference between this embodiment and Embodiment 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 4wt%, and the pore size of the molecular sieve MCM-41 is adjusted to 4.7nm.

[0042] Example 11: The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 5wt%, correspondingly reducing the N,N-dimethylacetamide solvent, and the pore size of the molecular sieve MCM-41 is adjusted to 4.7nm.

[0043] Example 12: The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 6wt%, correspondingly reducing the N,N-dimethylacetamide solvent, and the pore size of the molecular sieve MCM-41 is adjusted to 4.7nm.

[0044] Example 13: The only difference between this embodiment and Embodiment 1 is that the pore size of the molecular sieve MCM-41 is adjusted to 5.1 nm.

[0045] Example 14: The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 2wt%, correspondingly reducing the N,N-dimethylacetamide solvent, and the pore size of the molecular sieve MCM-41 is adjusted to 5.1nm.

[0046] Example 15: The only difference between this embodiment and Example 1 is that the amount of molecular sieve MCM-41 is adjusted to 3 wt%, correspondingly reducing the amount of N,N-dimethylacetamide solvent, and the pore size of molecular sieve MCM-41 is adjusted to 5.1 nm.

[0047] Example 16: The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 4wt%, correspondingly reducing the N,N-dimethylacetamide solvent, and the pore size of the molecular sieve MCM-41 is adjusted to 5.1nm.

[0048] Example 17: The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 5wt%, correspondingly reducing the N,N-dimethylacetamide solvent, and the pore size of the molecular sieve MCM-41 is adjusted to 5.1nm.

[0049] Example 18: The only difference between this embodiment and Example 1 is that the 1wt% molecular sieve MCM-41 is adjusted to 6wt%, correspondingly reducing the N,N-dimethylacetamide solvent, and the pore size of the molecular sieve MCM-41 is adjusted to 5.1nm.

[0050] Example 19: The only difference between this embodiment and Embodiment 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, and the pore size of molecular sieve MCM-48 is 3.6 nm.

[0051] Example 20: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 2wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 3.6nm.

[0052] Example 21: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 3wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 3.6nm.

[0053] Example 22: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 4wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 3.6nm.

[0054] Example 23: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 5wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 3.6nm.

[0055] Example 24: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 6wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 3.6nm.

[0056] Example 25: The only difference between this embodiment and Embodiment 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, and the pore size of molecular sieve MCM-48 is 4.7 nm.

[0057] Example 26: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 2wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 4.7nm.

[0058] Example 27: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 3wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 4.7nm.

[0059] Example 28: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 4wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 4.7nm.

[0060] Example 29: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 5wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 4.7nm.

[0061] Example 30: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 6wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 4.7nm.

[0062] Example 31: The only difference between this embodiment and Embodiment 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, and the pore size of molecular sieve MCM-48 is 5.1 nm.

[0063] Example 32: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 2wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 5.1nm.

[0064] Example 33: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 3wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 5.1nm.

[0065] Example 34: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 4wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 5.1nm.

[0066] Example 35: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 5wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 5.1nm.

[0067] Example 36: The only difference between this embodiment and Example 1 is that molecular sieve MCM-41 is replaced with molecular sieve MCM-48, the mass fraction is adjusted to 6wt%, the N,N-dimethylacetamide solvent is reduced accordingly, and the pore size of molecular sieve MCM-48 is 5.1nm.

[0068] Comparative Example 1: First, 15 wt% polyethersulfone (PES) and 3 wt% polyvinylpyrrolidone (PVP, K30) were mixed in 82 wt% N,N-dimethylacetamide (DMAC) solvent and mechanically stirred at 60°C for 6 hours until a uniform and clear casting solution was formed.

[0069] Then, the casting solution is allowed to cool naturally to room temperature (about 25°C) and allowed to stand for 12 hours to deaerate, so as to completely remove the air bubbles introduced during the stirring process and obtain the deaerated casting solution.

[0070] Next, the degassed casting liquid is placed into the feed trough of the film scraper. The gap between the scraper and the clean glass substrate is controlled to be 200 micrometers. The film is scraped at a constant speed of 2 meters per minute to obtain the nascent film.

[0071] Finally, the nascent membrane was placed on a glass plate, and the entire glass plate containing the nascent membrane was immersed in deionized water at 25°C for 24 hours to undergo phase transformation, thus obtaining the matrix membrane.

[0072] Comparative Example 2: First, 15 wt% polysulfone (PSF) and 3 wt% polyvinylpyrrolidone (PVP, K30) were mixed in 82 wt% N,N-dimethylacetamide (DMAC) solvent and mechanically stirred at 60°C for 6 hours until a uniform and clear casting solution was formed.

[0073] Then, the casting solution is allowed to cool naturally to room temperature (about 25°C) and allowed to stand for 12 hours to deaerate, so as to completely remove the air bubbles introduced during the stirring process and obtain the deaerated casting solution.

[0074] Next, the degassed casting liquid is placed into the feed trough of the film scraper. The gap between the scraper and the clean glass substrate is controlled to be 200 micrometers. The film is scraped at a constant speed of 2 meters per minute to obtain the nascent film.

[0075] Finally, the nascent membrane was placed on a glass plate, and the entire glass plate containing the nascent membrane was immersed in deionized water at 25°C for 24 hours to undergo phase transformation, thus obtaining the matrix membrane.

[0076] The performance of the matrix membranes prepared in Examples 1-36 and Comparative Examples 1 and 2 is analyzed below.

[0077] First, a molecular toxin removal test was performed on the product matrix membrane. The specific test method was as follows: a simulated solution (lysozyme) and a dialysate (water) were prepared. The product matrix membrane was positioned on both sides of the osmosis device, and toxins in the simulated solution were allowed to permeate through the membrane at a constant temperature of 37°C. Samples were taken periodically, and the toxin concentration on the dialysate side was measured using ultraviolet spectrophotometry. The removal rate was calculated as (toxin concentration after removal treatment / toxin concentration before removal treatment × 100%). The results are shown in Table 1.

[0078] Table 1: Clearance test results of matrix membranes prepared in Examples 1-36 and Comparative Examples 1 and 2

[0079] As can be seen from the data in Table 1, the removal rate of the pure polymer membrane (Comparative Examples 1 and 2) is significantly lower than that of the mixed matrix membrane of the molecular sieve. This is because the polymer has a non-static structure and the molecular chains are arranged in a disordered manner, making it difficult to form regular channels during phase separation.

[0080] Comparative examples 1-36 show that molecular sieve MCM-41 has a better toxin removal effect than molecular sieve MCM-48. Furthermore, the toxin removal rate increases with the increase of the amount of molecular sieve MCM-41 added. The removal effect on medium molecular toxins is optimal when the addition amount is 5wt% and the pore size is 5.1nm. This is because molecular sieve MCM-41 has regular pores and high β2-microglobulin size matching. The addition amount of 5wt% makes molecular sieve MCM-41 uniformly dispersed in the polymer matrix without agglomeration. Thus, through a precise sieving mechanism, it overcomes the limitation of low removal rate of traditional pure polymer membranes.

[0081] Next, the X-ray diffraction spectra of the molecular sieve mixed matrix membranes prepared in Examples 13-17, which showed better toxin removal effects, and the pure polymer matrix membrane prepared in Comparative Example 1 were compared. The results are as follows: Figure 1 As shown, all mixed matrix membranes containing molecular sieve MCM-41 exhibited corresponding diffraction peaks at the positions of the characteristic peaks of molecular sieve MCM-41. This directly proves that molecular sieve MCM-41 has been successfully incorporated into the PES membrane, and its ordered pore structure has been preserved and not destroyed after incorporation.

[0082] Then, the water contact angle of the molecular sieve mixed matrix membranes prepared in Examples 13-17 and the pure polymer matrix membrane prepared in Comparative Example 1 was tested, and the test results are as follows: Figure 2 As shown, it can be seen that as the amount of molecular sieve MCM-41 added increases, the water contact angle decreases and the hydrophilicity of the matrix membrane increases. This effectively demonstrates that water and toxins are more likely to adhere to the membrane surface and enter the pores.

[0083] Finally, porosity analysis was performed on the molecular sieve mixed matrix membranes prepared in Examples 13-17 and the pure polymer matrix membrane prepared in Comparative Example 1. The results are as follows: Figure 3 As shown, the porosity increases continuously with the continuous increase of the amount of molecular sieve MCM-41 added.

[0084] However, it should be noted that more MCM-41 molecular sieve is not necessarily better. When the amount of MCM-41 molecular sieve added increases to a certain level ( Figure 3 (Not shown) The porosity will decrease after reaching its maximum value. This phenomenon is caused by particle agglomeration, where the compatibility between the polymer and the molecular sieve has reached its limit.

[0085] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the technical principles of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A method for preparing a mixed matrix membrane of molecular sieves, characterized in that, include: After uniformly mixing the biocompatible polymer, molecular sieve, pore-forming agent and non-aqueous organic solvent, the mixture is cooled to room temperature and allowed to stand for degassing for 12-24 hours to obtain the casting solution. The casting solution is poured into a film scraper to obtain the primary film; The nascent membrane was immersed in an aqueous non-solvent for phase transformation to obtain a molecular sieve mixed matrix membrane. The phase transformation was carried out at 20-25°C for 20-28 hours. The casting solution contains 10-25 wt% biocompatible polymer, 4-5 wt% molecular sieve, 1-5 wt% pore-forming agent and 55-88 wt% non-aqueous organic solvent. The biocompatible polymer is polyethersulfone; the molecular sieve is MCM-41 with a pore size range of 3.6~5.1 nm; and the porogen is one or more of polyvinylpyrrolidone and polyethylene glycol.

2. The method for preparing a molecular sieve mixed matrix membrane according to claim 1, characterized in that, The molecular weight range of the biocompatible polymer is 20,000 to 80,000 g / mol.

3. The method for preparing a molecular sieve mixed matrix membrane according to claim 1, characterized in that, The non-aqueous organic solvent is one or more of N,N-dimethylacetamide, N,N-dimethylformamide, N,N-dimethylpyrrolidone, and dimethyl sulfoxide.

4. The method of claim 1, wherein the mixed matrix membrane is a molecular sieve mixed matrix membrane. The parameters of the film scraping machine include a gap range of 150~250 micrometers between the scraper and the clean glass substrate, and scraping at a constant speed of 1~3 meters / minute.

5. A mixed matrix membrane of molecular sieves, characterized in that, The membrane was prepared by the method described in any one of claims 1 to 4.

6. An application of the molecular sieve mixed matrix membrane according to claim 5, characterized in that, This includes passing blood through a molecular sieve-mixed matrix membrane to remove β2-microglobulin from the blood.

Citation Information

Patent Citations

  • Fe-MCM-41 / CA blend film and preparing method and application thereof

    CN106277163A